| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.075 | 0.01 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.15 | 0.02 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |